¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inflammatory linear verrucous epidermal nevus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • linear perspective
    ¼±»óÅõ½Ã
  • linear phased array
    ¼±ÇüÀ§»óÂ÷¹è¿­, ÁÙÀ§»óÂ÷¹è¿­
  • linear regression
    ¼±Çüȸ±Í
  • linear scale
    ±Õµî´«±Ý
  • linear scan
    ¼±½ºÄµ
  • linear scleroderma
    ¼±ÇǺΰæÈ­Áõ
  • linear sequenced array
    ¼±Çü¼øÂ÷¹è¿­, ÁÙ¸ð¾ç¼ø¼­¹è¿­
  • linear shadow
    ¼±À½¿µ
  • linear switched array
    ¼±Çü±³´ë½Ä¹è¿­, ÁÙ±³´ë½Ä¹è¿­
  • linear transducer
    ¼±ÇüŽÃËÀÚ
  • linear type constitution
    ¼±ÇüüÇü
  • acantholytic dyskeratotic nevus
    °¡½Ã¼¼Æ÷ºÐ¸®ÀÌ»ó°¢È­¸ð¹Ý, ±Ø¼¼Æ÷ÇØ¸®ÀÌ»ó°¢È­¸ð¹Ý
  • angiomatosus nevus
    Ç÷°ü¸ð¹Ý
  • apocrine nevus
    ¾ÆÆ÷Å©¸°¸ð¹Ý
  • achromic nevus
    Å»»ö¸ð¹Ý, ¹«»ö¸ð¹Ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • linear attenuation coefficient
    ¼±Çü°¨¼è°è¼ö
  • linear type constitution
    ¼±ÇüüÇü
  • linear density
    ¼±À½¿µ
  • linear lichenoid dermatosis
    ¼±»óż±¸ð¾çÇǺκ´
  • linear equation
    ÀÏÂ÷¹æÁ¤½Ä
  • linear fracture
    ¼±»ó°ñÀý
  • linear skull fracture
    ¼±»ó¸Ó¸®°ñÀý, µÎ°³°ñ¼±»ó°ñÀý
  • general linear model
    ÀϹݼ±»ó¸ðµ¨
  • high linear energy transfer radiation
    °í¼±Çü¿¡³ÊÁöÀüÀ̹æ»ç¼±
  • linear
    ÁÙ¸ð¾ç-, ¼±Çü-, ¼±»ó-
  • linear molecule
    ¼±ÇüºÐÀÚ
  • linear perspective
    ¼±»óÅõ½Ã
  • linear regression
    ¼±Çüȸ±Í
  • linear scale
    ±Õµî´«±Ý
  • linear scan
    ¼±½ºÄµ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • inflammatory carcinoma
    ¿°Áõ¼º ¾ÏÁ¾(¡­ äßðþ)
  • inflammatory diarrhea
    ¿°Áõ¼º ¼³»ç.
  • inflammatory erythema
    ¿°Áõ¼º È«¹Ý
  • inflammatory fracture
    ¿°Áõ¼º °ñÀý(æúñøàõÍéï¹).
  • inflammatory pain
    ¿°Áõ¼º µ¿Åë.
  • inflammatory pseudotumor
    ¿°Áõ°¡¼ºÁ¾¾ç
  • inflammatory pseudotumor
    ¿°Áõ¼º °¡Á¾¾ç.(¡­ Ê£ðþåË)
  • inflammatory tissue reaction
    ¿°Áõ¼º Á¶Á÷¹ÝÀÀ
  • inflammatory trismus
    ¿°Áõ¼º °³±¸Àå¾Ö.
  • nonsteroidal anti-inflammatory drug
    ºñ½ºÅ×·ÎÀ̵强 Ç׿°Áõ¾à
  • nonsteroidal anti-inflammatory drug
    ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°Á¦
  • pelvic inflammatory disease
    °ñ¹Ý¿°Áõ¼º Áúȯ.
  • pelvic inflammatory disease
    °ñ¹Ý¿°Áúȯ(ÍéÚïæúòðü´)
  • pelvic inflammatory disease(PID)
    °ñ¹Ý³»°¨¿°
  • systemic inflammatory response sydrome
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
DEJ Dermal-Epidermal Junction
ENKAF Epidermal-derived NK cell-Activating Factor
ETAF Epidermal cell derived Thymocyte Activating Factor
TEN Toxic Epidermal Necrolysis
DEJ, dej dentino-enamel junction; dermo-epidermal junction
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
LET Linear Energy Transfer
LAD Linear IgA Disease
LABD Linear IgA bullous dermatosis
LPC Linear Predictive Coding
LQ Linear Quadratic
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inflammatory hyperplasia
    ¿°Áõ¼º °úÇü¼º, ¿°Áõ¼º Áõ½Ä
    ¿°Áõ¿¡ ÀÇÇÏ¿© »ý±â´Â °úÇü¼º.
  • inflammatory joint disorder
    ¿°Áõ¼º °üÀý Àå¾Ö
  • inflammatory of jaw
    ÅÎÀÇ ¿°Áõ¼º
  • inflammatory papillary hyperpalsia
    ¿°Áõ¼º À¯µÎÁõ½Ä
    ¹ÝÀÀ¼º º´¼Ò·Î¼­ °¡Ã¶¼º º¸Ã¶¹°ÀÇ Áö¼ÓÀû »ç¿ë°ú °ü·ÃÀÌ ÀÖ´Ù. ÀÇÄ¡ ÇϹæ Á¡¸·¿¡ »ý±ä Ä­µð´ÙÁõÀº °æ±¸°³°¡ ÀÌ·¯ÇÑ Áõ½Ä¼º Á¶Á÷ ¹ÝÀºÀ» ÀÏÀ¸Å°´Â ÀڱؿøÀÌ µÈ´Ù. °æ±¸°³¿¡ ¸¹Àº ¼ÒÀ¯µÎÀÇ ºñÈİ¡ ³ªÅ¸³ª´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÀÚ°¥ ¸ð¾ç¿¡¼­ °áÀýÇü ºñÈÄ´Â ±¸°³¸é¿¡¼­´Â ±ºÁýÈ­µÇ¾î ³ªÅ¸³ª³ª Ä¡Á¶ Á¡¸·¿¡¼­´Â ´ú ¸íÈ®Çϰųª ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • inflammatory reaction
    ¿°Áõ ¹ÝÀÀ
    ¿°Áõ ÀÎÀÚ°¡ »ýü¿¡ ÀÛ¿ëÇÏ¸é »ýÃ¼Ãø¿¡´Â ¹æ¾î±â´ÉÀÌ »ý±ä´Ù. ±× ¿°Áõ¼Ò¿¡¼­ÀÇ Ç×ü³ª È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ µîÀÇ È­Çй°ÁúÀ» ÇÔÀ¯ÇÑ Ç÷Àå ¼ººÐÀ̳ª Á¶Á÷¾×ÀÇ ±¹¼ÒÀû »ïÃâ, ¹éÇ÷±¸ÀÇ Ä§À±, ȸº¹À» À§ÇÑ ¼¶À¯ Áõ»ý µîÀÇ »ýÃ¼Ãø¿¡ »ý±â´Â ¹ÝÀÀ Çö»óÀ» ¸»ÇÑ´Ù. ¿°Áõ ÀÎÀÚÀÇ Á¾·ù, ¾çÀ̳ª »ýÃ¼ÃøÀÇ »óÅ¿¡ µû¶ó¼­ ¿°Áõ ¹ÝÀÀÀÌ »ý±â´Â ¾ç»óÀº ´Ù¸£´Ù.
  • inflammatory resorption
    ¿°Áõ¼º Èí¼ö
  • inflammatory tissue
    ¿°Áõ Á¶Á÷
  • non-inflammatory
    ºñ¿°Áõ¼º
  • pelvic inflammatory disease
    °ñ¹Ý¿° Áúȯ
  • primary non-inflammatory, myogenous pain disorder
    ¿ø¹ß¼ºÀÇ ºñ¿°Áõ¼º ±ÙÀ° µ¿Åë Àå¾Ö
  • acrosyringeal nevus
    Ç¥Çdz» ÇѰü ¸ð¹Ý
  • adnexal nevus
    ºÎ¼Ó±â
  • basal cell nevus
    ±âÀú ¼¼Æ÷ ¸ð¹Ý
  • blue nevus
    û»ö ¸ð¹Ý
  • cellular blue nevus
    ¼¼Æ÷¼º û»ö ¸ð¹Ý
    û»ö ¸ð¹ÝÀÇ Æ¯ÀÌÇÑ º¯ÇüÀ¸·Î¼­ ÀÓ»óÀû ¹× Á¶Á÷ÇÐÀûÀ¸·Î ¾Ç¼º Èæ»öÁ¾À¸·Î ¿ÀÀεDZ⠽±´Ù. À̰ÍÀº µÐºÎ¿Í õ¹Ì°ñ ºÎÀ§¿¡ È£¹ßÇϸç Ä¿´Ù¶õ û»ö ¶Ç´Â Èæ»öÀÇ ´Ü´ÜÇÑ °áÀý·Î ³ªÅ¸³­´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
macrophage inflammatory protein <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other.
They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells.
They most likely also play a significant role in respiratory tract defenses.
(20 Sep 2002)
pelvic inflammatory disease <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections.
(27 Sep 1997)
chronic inflammatory demyelinating polyneuropathy An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone.
(05 Mar 2000)
chronic inflammatory polyneuropathy <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response.
The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable.
Origin: Gr. Pathos = disease
(27 Sep 1997)
non-steroidal anti-inflammatory <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions.
Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate.
A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity.
Acronym: NSAID
(05 May 2002)
non-steroidal anti-inflammatory drug <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions.
Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate.
A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity.
Acronym: NSAID
(05 May 2002)
desquamative inflammatory vaginitis An acute inflammation of the vagina of unknown cause, characterised by grayish pseudomembrane, free discharge, and easy bleeding on trauma; the discharge contains pus and immature epithelial cells, although oestrogen levels are normal.
Vaginitis emphysematosa, vaginitis characterised by accumulation of gas in small connective tissue spaces lined by foreign-body giant cells.
Synonym: pachyvaginitis cystica, vaginitis cystica.
(05 Mar 2000)
disease, pelvic inflammatory Despite its seeming lack of gender, this term is applied to women only. PID refers exclusively to ascending infection of the female genital tract above the cervix.
(12 Dec 1998)
inflammatory <pathology> Inflammation is the reaction of living tissues to injury, infection or irritation. Inflamed tissues are characterised by pain, swelling, redness and heat. Anything that stimulates the inflammatory response is said to be inflammatory.
See: inflammation.
(11 Jun 1998)
inflammatory bowel disease <disease> A general term that encompasses several disease processes, most commonly, ulcerative colitis and Crohn's disease.
(27 Sep 1997)
inflammatory bowel diseases Chronic, non-specific disorders of unknown aetiology. Includes crohn disease and ulcerative colitis. Extracolonic manifestations are often associated with inflammatory bowel disease (ibd) and involve the liver, joints and skin.
(12 Dec 1998)
inflammatory carcinoma <tumour> Carcinoma of the breast presenting with oedema, hyperaemia, tenderness, and rapid enlargment of the breast; microscopically, there is extensive invasion of dermal lymphatics by the carcinoma.
(05 Mar 2000)
inflammatory corpuscle A cell present in an exudate that assists in the organization of new tissue.
Synonym: exudation cell, inflammatory corpuscle, plastic corpuscle.
(05 Mar 2000)
inflammatory fibrous hyperplasia Overgrowth of tissue in the mucobuccal or labial fold, induced by chronic trauma from ill-fitting dentures.
Synonym: denture hyperplasia, epulis fissuratum.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á